First-in-human dose-escalation study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with non-small cell lung, pancreatic, or colorectal cancer.
Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Sonya Zabludoff(AstraZeneca (United Kingdom)), Annie Huynh(Nitto (United States)), Alexander I. Spira(Virginia Cancer Specialists), John Nemunaitis(Gradalis (United States)), Zhihong O’Brien(Nitto (United States)), Joachim Gullbo(Theradex Oncology (United States)), Zachary Albaugh(Theradex Oncology (United States)), Andrae Lavon Vandross(Texas Oncology), Hirva Mamdani(Wayne State University)
Cited by 13
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|719